Revance Therapeutics Renews Manufacturing Deal and Announces Executive Transition
Company Announcements

Revance Therapeutics Renews Manufacturing Deal and Announces Executive Transition

The latest update is out from Revance Therapeutics (RVNC).

Revance Therapeutics, Inc. has extended its agreement with Ajinomoto Bio-Pharma Services until December 31, 2027, for manufacturing services related to DAXXIFY® at their San Diego facility, with updated terms regarding product conformity and delay remedies. Additionally, the company’s President, Mr. Sjuts, will step down, receiving a severance package, which includes 18 months of his base salary and health benefits, and will remain as a consultant for a year to ensure a smooth transition and allow his equity awards to continue vesting.

For an in-depth examination of RVNC stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyNvidia trades on Dow for first time, Rivian reports downbeat Q3: Morning Buzz
TipRanks Auto-Generated NewsdeskRevance Therapeutics Reports Q3 Growth Amid Merger Plans
TheFlyClosing Bell Movers: Toast gains 19% afterhours after earnings beat
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App